Immunomedics Inc. (IMMU) Releases Promising Results of Published Leukemia Study
According to the American Cancer Society, approximately 3,040 children will be diagnosed with Acute Lymphoblastic Leukemia (ALL) in the United States this year. While the five-year survival rate for ALL in children is 87 percent, the prognosis for a child with relapsed ALL remains low. These harrowing statistics are pushing biopharmaceutical companies to continue to improve research efforts for the treatment of ALL. Immunomedics Inc. (Nasdaq: IMMU) is a biopharmaceutical company focused on the development of monoclonal antibodies for the treatment of cancer, autoimmune and other serious diseases. Utilizing its proprietary technologies, the company has created a pipeline of therapeutic…